Concepedia

Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Xiaowen Tang, Lin Yang, Zheng Li, Ansel P. Nalin, Haiping Dai, Ting Xu, Jia Yin, Fengtao You, Mingqing Zhu, Wenhong Shen,

PubMed · 2018 · 412 citations · 13 references

Full text

Open access

Concepts

Abstract

(5 billion) cells per patient, no significant adverse effects were observed. CAR NK-92 cells can be produced at much lower cost compared to CAR T cells, and we believe after being optimized, they will be widely accessible for the treatment of cancer.

References

13

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

E Liu, Yijiu Tong, Gianpietro Dotti et al. · Leukemia · 2017 · 811 citations

, , +16

Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.

Jiang-Hong Gong, Guitta Maki, Hans-G. Klingemann · PubMed · 1994 · 729 citations

, , +10

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Saar Gill, Sarah K. Tasian, Marco Ruella et al. · Blood · 2014 · 491 citations · Full text

, , +17

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

Jianjun Chu, Youcai Deng, D.M. Benson et al. · Leukemia · 2013 · 439 citations · Full text

, , +17

ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma

Congcong Zhang, Michael C. Burger, Lukas Jennewein et al. · JNCI Journal of the National Cancer Institute · 2015 · 388 citations · Full text

, , +17